Cantor Fitzgerald Equities Analysts Increase Earnings Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Regeneron Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will earn $37.72 per share for the year, up from their previous forecast of $37.66. Cantor Fitzgerald has a “Neutral” rating and a $925.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $38.80 per share.

A number of other research firms have also issued reports on REGN. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Barclays boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Trading Up 0.4 %

Shares of REGN stock opened at $900.16 on Tuesday. The business’s 50 day moving average is $952.07 and its two-hundred day moving average is $892.70. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a market cap of $98.80 billion, a PE ratio of 25.90, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the prior year, the firm posted $10.96 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. West Paces Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $31,000. MCF Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.